Latest Asia Pacific News

Austin Engineering reported a robust 22.2% revenue increase in FY25, driven by a strong North American expansion and improved margins in Asia Pacific. Despite some operational challenges in Chile, the company’s underlying profits soared, setting a confident tone for FY26.

Web Travel Group signals strong momentum heading into FY26, projecting record EBITDA and a robust $3.1 billion in first-half Total Transaction Value despite geopolitical headwinds.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Regal Partners Limited reported robust half-year results for 1H25, with funds under management reaching $17.7 billion and normalised net profit after tax hitting $44.8 million. The firm achieved record net inflows and maintained a strong balance sheet, signaling continued growth momentum.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Data#3 Limited reported a robust FY25 with $3 billion in gross sales and an 11.4% rise in net profit before tax, underpinned by cloud, security, and AI demand. The company’s FY26 strategy focuses on customer experience and operational excellence amid evolving IT sector trends.

Nuix Limited reported an 8% rise in Annualised Contract Value for FY25, driven by a remarkable 132% growth in its Nuix Neo platform. Despite flat revenue, the company achieved a 24.5% increase in Cash EBITDA and outlined a confident outlook for FY26.

Nuix Limited reported an 8% rise in Annualised Contract Value for FY25, powered by a surge in Nuix Neo sales, despite posting a net loss after tax. The company’s strategic pivot to higher-value contracts and technology restructuring sets the stage for FY26.

Nuix Limited reported a slight revenue increase to $221.5 million for FY25 but swung to a net loss of $9.2 million, weighed down by rising legal fees and restructuring costs. The company’s AI-driven Nuix Neo platform showed strong contract growth, while cash EBITDA improved significantly.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.